Sosei Heptares to Host R&D Day Highlighting its Innovative R&D and Late-Stage Development Progress
October 25, 2023 04:00 ET
|
Sosei Group Corporation
Tokyo, Japan and Cambridge, UK, 25 October 2023 – Sosei Group Corporation (“the Company”; TSE: 4565) will hold an R&D Day on Friday, 10 November 2023, at 4 pm JST. The meeting will be held...
Sosei Heptares’ President & CEO Chris Cargill Wins Executive of the Year at the Citeline Pharma Intelligence Awards Japan 2023
October 18, 2023 03:04 ET
|
Sosei Group Corporation
Tokyo, Japan, and Cambridge, UK, 18 October 2023 – Sosei Group Corporation (“Sosei Heptares” or “the Company”; TSE: 4565), an international biopharmaceutical company and world-leader in GPCR-focused...
Sosei Heptares and PharmEnable Therapeutics Expand Drug Discovery Collaboration
October 10, 2023 02:30 ET
|
Sosei Group Corporation
The collaboration combines Sosei Heptares’ leading structure-based drug design platform with PharmEnable’s advanced artificial intelligence-enabled platform for designing high quality novel chemistry...
Sosei Heptares Adds World-leading Expertise to its Scientific Advisory Board
September 20, 2023 02:30 ET
|
Sosei Group Corporation
Tokyo, Japan and Cambridge, UK, 20 September 2023 – Sosei Group Corporation (“the Company”; TSE: 4565) announces the appointment of four new members to its Scientific Advisory Board (SAB) to advise on...
Sosei Heptares’ partner Neurocrine Biosciences Initiates Phase 1 Clinical Study Evaluating Effects of NBI-1117570 in Healthy Adults
September 11, 2023 19:01 ET
|
Sosei Group Corporation
NBI-1117570 is an investigational, oral, muscarinic M1/M4 selective dual agonist discovered by Sosei Heptares that may have the potential to treat neurological and neuropsychiatric...
Sosei Heptares and Cancer Research UK Announce the Dosing of the First Patient in a Phase I/IIa Trial with Cancer Immunotherapy Drug HTL0039732
August 10, 2023 02:52 ET
|
Sosei Group Corporation
HTL0039732 is a novel EP4 antagonist designed by Sosei Heptares with potential to treat a wide range of cancers in combination with other immunotherapies Tokyo, Japan, London and Cambridge, UK, 10...
Sosei Heptares Operational Highlights and Consolidated Results for the Second Quarter and First Half of 2023
August 04, 2023 02:37 ET
|
Sosei Group Corporation
Tokyo, Japan and Cambridge, UK, 4 August 2023 – Sosei Group Corporation (“the Company”; TSE: 4565) provides an update on operational activities and reports its consolidated results for the second...
Sosei Heptares - Investor and Press Conference on Today’s Announcement Regarding the Acquisition and License Transaction with Idorsia
July 20, 2023 02:31 ET
|
Sosei Group Corporation
Tokyo, Japan and Cambridge, UK, 20 July 2023 – Sosei Group Corporation (“the Company”; TSE: 4565), will hold an investor and press conference on today’s announcement; “Sosei Heptares Acquires...
Sosei Heptares Acquires Idorsia’s Pharmaceuticals Business in Japan and APAC (ex-China), Accelerating its Transformation into a Fully Integrated Biopharmaceutical Company
July 20, 2023 02:30 ET
|
Sosei Group Corporation
Transaction adds complementary late-stage clinical development capability with profitable and fast-growing commercial operations in JapanLean, go-to-market commercial model, well positioned to scale...
Sosei Heptares Webinar Presentation for Q2 FY2023 Financial Results
July 11, 2023 03:00 ET
|
Sosei Group Corporation
Tokyo, Japan and Cambridge, UK, 11 July 2023 – Sosei Group Corporation (“the Company”; TSE: 4565) will announce its earnings results and present operational highlights for the 6 months ended 30 June...